Real-time disaster intelligence, alerts, and response tools.
Tuesday, April 21, 2026
[ad_1] XtalFold™ utilizes sequence information alone to model the interaction between biomolecules, which forms the foundation of biotherapeutics like monoclonal antibodies. In rigorous benchmark studies, XtalFold™ achieved state-of-the-art performance in terms of overall success rate […]
[ad_1] HERZLIYA, Israel and CALGARY, Alberta, Oct. 11, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce […]
[ad_1] Product is First Non-Factor and Once-Weekly Treatment for Hemophilia B SILVER SPRING, Md., Oct. 11, 2024 /PRNewswire/ — Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or […]
[ad_1] Advisory Committee Voted 10 to 6 in Favor, Concluding that Elamipretide is Effective for the Treatment of Barth Syndrome Elamipretide NDA Received Priority Review with a PDUFA Action Date of January 29, 2025 If Approved, Elamipretide […]
[ad_1] UCB will contribute 14 presentations, including an oral presentation, selected to feature across the AANEM and MGFA meeting, emphasizing UCB’s leadership in neuromuscular research Presentations showcase new data for UCB’s gMG treatments, including post hoc […]
